Extracellular Vesicles aS Predictors of ANtidepressant Outcomes in Pediatric Anxiety (EV-SoPRANO)
Pediatric Anxiety Treatment Study
Sponsor: New York State Psychiatric InstituteColumbia University
Enrolling: Male and Female Patients
Study Length: 14 Weeks
Clinic Visits: 4
IRB Number: 7890
U.S. Govt. ID: NCT04221997
Contact: Lily Gabay: 954-478-1589 / lily.gabay@nyspi.columbia.edu
Additional Study Information: Sertraline (also known as Zoloft) is an FDA approved medication that is used to treat anxiety in children and adolescents. We aim to better understand how children and adolescents with anxiety respond to sertraline and whether we can predict medication response. If your child is eligible, he or she can participate in a research study and will receive both a clinical evaluation and 14 weeks of medication at no cost to you. Your child may also have access to a therapeutic school on the premises.
This study is closed
Amir Levine, MD
Do You Qualify?
Is your child between the ages of 8 and 17 years old? Yes No
Is your child currently taking sertraline (Zoloft)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Lily Gabay